| (USD) | Jun 2024 | Q/Q |
|---|---|---|
| Revenue | 7MM | -76% |
| Operating Income | -139MM | +22% |
| Operating Expenses | 146MM | - |
| Net Income | -147MM | +37% |
| R&D | 114.2MM | +2% |
| G&A | 31.8MM | +2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
We recently compiled a list of 10 Stocks That Will Change the World. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against the other stocks. If we were to try and summarize one of the biggest ways how to make money on the stock market, it’d […]
As you might know, Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) last week released its latest second-quarter, and things...
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation. Or, as noted by the Cleveland Clinic, when you have the wrong amount of genetic material. It’s even helped address a form of inherited blindness in patients, including children. According to Penn Medicine News, “nearly half reported measurable improvements
Merck stopped a Phase 3 TIGIT study for futility. Elsewhere, shares in Cabaletta Bio sank on safety worries and Vertex secured Casgevy reimbursement in England.
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of -8.26% and 65.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarterSelected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyOn track to initiate the Phase 3 study of NTLA-2001 for the treatment of
As a rule of thumb, you want to make market decisions based on a wide range of assessments and not just on the recommendation of a popular investor. That said, if you had to trade with a particular individual, you can do a lot worse than so-called Cathie Wood stocks. An entrepreneur and a tech visionary, Wood is considered a star stock picker. She’s the founder of ARK Invest, which features around $60 billion worth of assets. Part of the reason for considering the ideas she supports is longevity
The popular growth-stock investor added to these three existing positions on Wednesday.
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. Al